Reaction

Neck Mass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,792 reports · 51 co-occurring drugs

As of the last recalculation, Neck Mass appears in 2,792 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is INDOMETHACIN (PRR 14.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Indomethacin	26	14.8	14.8
Octreotide Acetate	56	13.9	13.9
Sulfasalazine	116	11.5	11.5
Meperidine Hydrochloride	12	9.7	9.8
Hydroxychloroquine	94	9.7	9.7
Hydroxychloroquine Sulfate	109	9.2	9.3
Naproxen Sodium Tablet, Coated	16	8.9	8.9
Naproxen Sodium, Coated Tablets	16	8.9	8.9
Naproxen Sodium 220Mg	16	8.8	8.9
Polatuzumab Vedotin	11	8.4	8.4
Leflunomide	106	7.8	7.8
Oral Semaglutide	74	7.7	7.7
Dulaglutide	81	7.0	7.0
Liraglutide	44	6.7	6.7
Lovastatin	22	6.4	6.4
Ribociclib	25	5.9	6.0
Doxepin Hydrochloride	10	5.9	5.9
Folic Acid	185	5.9	5.9
Cyclobenzaprine Hydrochloride	7	5.8	5.8
Certolizumab Pegol	89	5.8	5.8
Tocilizumab	81	5.4	5.4
Ibrutinib	57	5.3	5.4
Anastrozole Tablets	15	5.2	5.2
Tofacitinib	122	5.1	5.1
Fulvestrant	22	5.0	5.0
Acalabrutinib	8	4.9	4.9
Bendamustine Hcl	10	4.8	4.8
Golimumab	54	4.8	4.8
Duloxetine Hydrochloride	116	4.8	4.8
Abatacept	80	4.4	4.4
Naltrexone Hydrochloride And Bupropion Hydrochloride	5	4.4	4.4
Vemurafenib	7	4.4	4.4
Infliximab	121	4.3	4.3
Adalimumab	360	4.2	4.2
Carboxymethylcellulose Sodium	5	4.0	4.0
Agalsidase Beta	4	3.2	3.2
Dabrafenib	9	3.2	3.2
Obinutuzumab	7	3.2	3.2
Etanercept	237	3.1	3.1
Tirzepatide	64	3.0	3.0
Venetoclax	23	2.8	2.8
Benralizumab	7	2.6	2.6
Rucaparib	3	2.5	2.5
Avapritinib	4	2.5	2.5
Velpatasvir And Sofosbuvir	4	2.3	2.3
Cabozantinib	13	2.0	2.0
Somatropin	13	1.3	1.3
Pirfenidone	7	1.3	1.3
Abaloparatide	5	1.3	1.3
Pomalidomide	16	1.2	1.2
Valbenazine	3	0.9	0.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.